Medifast Q3 Loss Widens, Sales Decline 36% YoY Amid Strategy Shift to Metabolic Health

Medifast reported a Q3 loss of 21 cents per share, wider than the Zacks Consensus Estimate, and net revenues of $89.4 million, down 36.2% YoY. The number of active earning OPTAVIA coaches declined 35% YoY to 19,500. Gross profit fell 41.2% YoY to $62.2 million, and SG&A expenses decreased 36% YoY to $66.2 million. The company is shifting its strategy from a weight-loss to a metabolic health leader, focusing on its coach-guided, clinically proven system.